Upper tract urothelial carcinoma: Impact of time to surgery

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 3, 2012, Pages 266-272

  Sundi, Debasish ^a,b   Svatek, Robert S ^a   Margulis, Vitaly ^a,c   Wood, Christopher G ^a   Matin, Surena F ^a   Dinney, Colin P ^a   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Delayed surgery; Neoadjuvant chemotherapy; Nephroureterectomy; Upper tract urothelial carcinoma

Indexed keywords

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; THERAPY DELAY; TRANSITIONAL CELL CARCINOMA;

AGED; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84860303318     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.04.002     Document Type: Article

References (22)

1. Schmauz R., Cole P. Epidemiology of cancer of the renal pelvis and ureter. J Natl Cancer Inst 1974, 52:1431-1434.
2. Brown G.A., Matin S.F., Busby J.E., et al. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 2007, 70:252-256.
3. Hall M.C., Womack S., Sagalowsky A.I., et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: A 30-year experience in 252 patients. Urology 1998, 52:594-601.
4. Bamias A., Deliveliotis C., Fountzilas G., et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: A study by the Hellenic Cooperative Oncology Group. J Clin Oncol 2004, 22:2150-2154.
5. Lake A.M., Roberts W.W. Surgical management of upper tract transitional cell carcinoma. J Natl Comprehensive Cancer Network 2006, 4:1015-1018.
6. Brown G.A., Busby J.E., Wood C.G., et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?. BJU Int 2006, 98:1176-1180.
7. Munoz J.J., Ellison L.M. Upper tract urothelial neoplasms: incidence and survival during the last two decades. J Urol 2000, 164:1523-1525.
8. Kwak C., Lee S.E., Jeong I.G., et al. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 2006, 68:53-57.
9. Bamias A., Moulopoulos L.A., Koutras A., et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 2006, 106:297-303.
10. Lee C.T., Madii R., Daignault S., et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease-specific and overall survival. J Urology 2006, 175:1262-1267.
11. Lucas S.M., Svatek R.S., Olgin G., et al. Conservative management in selected patients with upper tract urothelial carcinoma compares favorably with early radical surgery. BJU Int 2008, 102:172-176.
12. Sternberg C.N. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. Semin Oncol 2007, 34:122-128.
13. Sagalowsky A.I. Management of urothelial tumors of the renal pelvis and ureter 2002, 2845-2875. WB Saunders, Philadelphia (PA).
14. Daneshmand S., Quek M.L., Huffman J.L. Endoscopic management of upper urinary tract transitional cell carcinoma: Long-term experience. Cancer 2003, 98:55-60.
15. Keeley F.X., Bibbo M., Bagley D.H. Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol 1997, 157:1560-1565.
16. Lam J.S., Gupta M. Ureteroscopic management of upper tract transitional cell carcinoma. Urol Clin North Am 2004, 31:115-128.
17. Boorjian S., Ng C., Munver R., et al. Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. Urology 2005, 66:283-287.
18. May M., Nitzke T., Helke C., et al. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. Scand J Urol Nephrol 2004, 38:231-235.
19. Sanchez-Ortiz R.F., Huang W.C., Mick R., et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003, 169:110-115. Discussion 115.
20. Igawa M., Urakami S., Shiina H., et al. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int 1995, 55:74-77.
21. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
22. Kirkalia Z. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma. Time to change the treatment paradigm?. Eur Urol 2007, 51:1141-1142.